+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A novel orally active dual inhibitor of VEGF receptor 1 and 2 tyrosine kinase KRN633 Anti-angiogenic and anti-tumor activity against human solid tumors



A novel orally active dual inhibitor of VEGF receptor 1 and 2 tyrosine kinase KRN633 Anti-angiogenic and anti-tumor activity against human solid tumors



Proceedings of the American Association for Cancer Research Annual Meeting 43: 175




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034311513

Download citation: RISBibTeXText


Related references

CEP-7055 An orally-active VEGF-R kinase inhibitor with potent anti-angiogenic activity and anti-tumor efficacy against human tumor xenograft growth. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1080, 2002

An orally active inhibitor of VEGF receptor tyrosine kinase with potent anti-tumor activity. Proceedings of the American Association for Cancer Research Annual Meeting 42: 587, 2001

Combining a selective VEGF receptor inhibitor and a selective PDGF receptor inhibitor recapitulates the anti-tumor efficacy of SU11248, a selective oral multi-targeted tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity through targeting PDGFR, VEGFR, KIT and FLT3. Proceedings of the American Association for Cancer Research Annual Meeting 44: 970, 2003

Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of VEGF and PDGF receptor tyrosine kinase. 2013

Effects of ZD6474, an orally active inhibitor of VEGF receptor tyrosine kinase, in patients with solid tumors Results from a phase I study. European Journal of Cancer 37(Suppl. 6): S73, 2001

Anti-angiogenic and anti-tumor activity of a novel VEGFR-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Proceedings of the American Association for Cancer Research Annual Meeting 44: 604, 2003

Discovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays. African Journal of Traditional Complementary and Alternative Medicines 9(3): 431-439, 2012

JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Molecular Cancer Therapeutics 8(11): 3151-3161, 2009

Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window. Molecular Cancer Therapeutics 5(1): 80-88, 2006

ZD4190 An orally active inhibitor of VEGF receptor tyrosine kinase activity. British Journal of Cancer 80(Suppl. 2): 92, 1999

Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase Inhibitors. Cancer and Metastasis Reviews 18(4): 473-481, 1999

Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Reviews 18(4): 473-481, 1999

ZD6474 Design, synthesis and structure activity relationship of a novel, orally active VEGF receptor tyrosine kinase inhibitor. Proceedings of the American Association for Cancer Research Annual Meeting 42: 587, 2001

Targeting vascular endothelial growth factor for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer & Metastasis Reviews 18(4): 473-481, 1999

Anti-proliferative and anti-invasive EGFR amplification dependent and anti-angiogenic EGFR amplification independent activity of ZD1839 tyrosine kinase inhibitor on human glioblastomas. Proceedings of the American Association for Cancer Research Annual Meeting 44: 203, 2003